Results 81 to 90 of about 113,281 (294)
Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP ...
Bhosekar V, Foley JE, Kozlovski P
core
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li +6 more
wiley +1 more source
Background To compare the effects of switching from dipeptidyl peptidase 4 (DPP-4) inhibitors to oral semaglutide on oxidative stress and glucose variability assessed by continuous glucose monitoring in patients with type 2 diabetes mellitus (T2DM ...
Makoto Ohara +10 more
doaj +1 more source
The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]
The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
Bundschuh Daniela S. +25 more
core +1 more source
Dipeptidyl-peptidase 4 is a novel targeted enzyme in type 2 diabetes mellitus (T2DM) therapy due to its regulatory effect on incretin; glucagon-like peptide 1 (GLP-1) that responsible for stimulating insulin and suppressing glucagon secretion.
Taib, Raihan +3 more
core +1 more source
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig +7 more
wiley +1 more source
DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor–associated angioedema who presented to the emergency department with ...
Ejikeme, Chidinma +9 more
core +2 more sources
The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin +6 more
doaj +1 more source
Untargeted peptide profiling investigates how S. thermophilus, Lb. bulgaricus, and endogenous milk enzymes impact proteolysis during early‐stage milk fermentation. ≥ 3000 identified peptides show the strongest influence of LB on the peptide profile and number of bioactive peptides. Shorter peptides are mostly formed by LB and hydrolyzed by ST.
Eva Beck +6 more
wiley +1 more source
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier +7 more
wiley +1 more source

